{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:45:31Z","timestamp":1763016331642,"version":"3.30.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":664,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p><jats:italic>Background:<\/jats:italic>Leukopenia is not infrequently encountered following solid organ transplantation, most often in the setting of cytomegalovirus (CMV) disease and\/or its treatment with ganciclovir. The present study was undertaken to determine the safety and efficacy of granulocyte colony\u2010stimulating factor (G\u2010CSF) in renal and liver transplant recipients with leukopenia.<jats:italic>Methods<\/jats:italic>: Between 1 June 1991 and 1 June 1998, patients received G\u2010CSF for 2 indications: 1) white blood cell count (WBC) &lt;3000\/mm<jats:sup>3<\/jats:sup>, with a decline from baseline; 2) to shorten the duration of leukopenia associated with chemotherapy. A retrospective review of the outcome of such therapy was undertaken.<jats:italic>Results:<\/jats:italic>50 patients were given 100 courses of treatment with G\u2010CSF; 35 of 168 liver transplant recipients (20.8%), 14 of 391 kidney transplant recipients (3.6%), and 1 of 4 recipients of combined liver\u2013kidney transplants (25.0%) received from 1 to 9 courses of G\u2010CSF. Presumed causes of leukopenia were identified as ganciclovir in 28 cases (28.0%), CMV in 21 (21.0%), chemotherapy in 12 (12.0%), sepsis in 11 (11.0%), azathioprine in 5 (5.0%), interferon in 3 (3.0%) and other causes in 20 cases (20.0%). The median length of therapy was 10.0 days (range 1\u2013154 days) and the average dose of daily G\u2010CSF received was 3.9\u00b11.5 \u03bcg\/kg\/day. The average WBC was (2.4\u00b11.3)\u00d710<jats:sup>3<\/jats:sup>\/\u03bcl at the beginning of therapy, and (13.8\u00b19.1)\u00d710<jats:sup>3<\/jats:sup>\/\u03bcl at the end of therapy. In 7 of 100 treatments (7.0%) a WBC of 5.0\u00d710<jats:sup>3<\/jats:sup>\/\u03bcl was not reached during G\u2010CSF therapy; in 6 of these 7 cases, G\u2010CSF therapy lasted fewer than 4 days. The mean time needed to reach a WBC count of 5\u00d710<jats:sup>3<\/jats:sup>\/\u03bcl was 3.7\u00b13.3 days among 71 patients who had daily WBC counts sent. Eight G\u2010CSF treatments (8.0%) were followed by episodes of rejection appearing during or within 2 months of treatment; 5 of them were biopsy\u2010documented. No relation was found between the highest WBC obtained during G\u2010CSF therapy and the risk of rejection. Eight patients (16.0%) died while receiving G\u2010CSF, all from infection. Six of these 8 patients were receiving G\u2010CSF for leukopenia secondary to sepsis. Overall, 25 patients (50.0%) received 49 courses of G\u2010CSF secondary to CMV and\/or ganciclovir therapy. In 40 of 49 courses (81.6%), ganciclovir could be continued at recommended doses. Twenty\u2010one of 22 patients (95.5%) with symptomatic CMV infection had a clinical response to ganciclovir. Sixteen of 18 patients (88.9%) treated for a CMV infection and followed with serial antigenemia assays attained microbiological cure; both patients who did not were infected with ganciclovir resistant CMV.<jats:italic>Conclusion:<\/jats:italic>G\u2010CSF was well tolerated in solid organ transplant recipients. It was particularly useful in patients with CMV disease, allowing optimal ganciclovir therapy (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#fn1\">Note<\/jats:ext-link>).<\/jats:p>","DOI":"10.1034\/j.1399-3062.2000.020104.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:25:54Z","timestamp":1047504354000},"page":"15-21","source":"Crossref","is-referenced-by-count":45,"title":["Safety and efficacy of granulocyte colony\u2010stimulating factor in kidney and liver transplant recipients"],"prefix":"10.1111","volume":"2","author":[{"given":"N.","family":"Turgeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.K.","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Basgoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.E.","family":"Tolkoff\u2010Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Doran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Cosimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.H.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_6_2_2","DOI":"10.1007\/978-1-4615-2490-8_24"},{"doi-asserted-by":"publisher","key":"e_1_2_6_3_2","DOI":"10.1056\/NEJM199207023270106"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_2","DOI":"10.1056\/NEJM199207093270207"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.V74.8.2644.2644","article-title":"Hematologic effects of recombinant human granulocyte colony\u2010stimulating factor in patients with malignancy.","volume":"74","author":"Lindemann A","year":"1989","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_6_6_2","DOI":"10.1056\/NEJM199706193362502"},{"key":"e_1_2_6_7_2","first-page":"1369","article-title":"Colony\u2010stimulating factor for treatment of leukopenia after kidney allografting.","volume":"23","author":"Tajima A","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_6_8_2","first-page":"1593","article-title":"Reversal of neutropenia with granulocyte colony\u2010stimulating factor without precipitating liver allograft rejection.","volume":"56","author":"Colquhoun SDB","year":"1993","journal-title":"Transplantation"},{"key":"e_1_2_6_9_2","first-page":"283","article-title":"Use of granulocyte\u2010macrophage colony\u2010stimulating factor in leukopenic renal transplant recipient.","volume":"26","author":"Morin MP","year":"1994","journal-title":"Transplant Proc"},{"key":"e_1_2_6_10_2","first-page":"3092","article-title":"Use of granulocyte\u2010macrophage colony\u2010stimulating factor for reversal of neutropenia following combined kidney\u2013pancreas transplantation.","volume":"27","author":"Squiers EC","year":"1995","journal-title":"Transplant Proc"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1097\/00007890-199506000-00009","article-title":"The use of granulocyte colony\u2010stimulating factor after liver transplantation.","volume":"59","author":"Foster PF","year":"1995","journal-title":"Transplantation"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1399-0012.1996.tb00638.x","article-title":"Role of granulocyte colony stimulating factor (G\u2010CSF) in reversing neutropenia in renal allograft recipients.","volume":"10","author":"Peddi VR","year":"1996","journal-title":"Clin Transplant"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1399-0012.1994.tb00940.x","article-title":"Management of the renal allograft recipient: immunosuppressive protocols for long\u2010term success.","volume":"8","author":"Delmonico FL","year":"1994","journal-title":"Clin Transplant"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_2","DOI":"10.1097\/00007890-199901270-00010"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/jcm.31.10.2824-2827.1993","article-title":"Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in patients with AIDS.","volume":"31","author":"Mazzulli T","year":"1993","journal-title":"J Clin Microbiol"},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_2","DOI":"10.1016\/0166-0934(90)90122-V"},{"unstructured":"RubinRH FishmanJA Tolkoff\u2010RubinNE et al.The effectiveness of intravenous followed by oral ganciclovir in the prevention of primary cytomegalovirus disease in organ transplant recipients.To be published.","key":"e_1_2_6_17_2"},{"doi-asserted-by":"publisher","key":"e_1_2_6_18_2","DOI":"10.1097\/00007890-199812270-00036"},{"doi-asserted-by":"publisher","key":"e_1_2_6_19_2","DOI":"10.1097\/00062752-199603010-00002"},{"key":"e_1_2_6_20_2","first-page":"2166","article-title":"Worsening of renal function in a renal transplant patient treated with granulocyte colony\u2010stimulating factor.","volume":"10","author":"Minguez C","year":"1995","journal-title":"Nephrol Dial Transplant"},{"doi-asserted-by":"publisher","key":"e_1_2_6_21_2","DOI":"10.1097\/00007890-199604150-00026"},{"doi-asserted-by":"publisher","key":"e_1_2_6_22_2","DOI":"10.1073\/pnas.87.4.1386"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1128\/jvi.71.6.4589-4598.1997","article-title":"Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes.","volume":"71","author":"Mayer A","year":"1997","journal-title":"J Virol"},{"doi-asserted-by":"publisher","key":"e_1_2_6_24_2","DOI":"10.1128\/AAC.31.3.452"},{"doi-asserted-by":"publisher","key":"e_1_2_6_25_2","DOI":"10.1097\/00007890-199204000-00041"},{"doi-asserted-by":"publisher","key":"e_1_2_6_26_2","DOI":"10.1097\/00007890-199410150-00024"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3062.2000.020104.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3062.2000.020104.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3062.2000.020104.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T10:25:27Z","timestamp":1733567127000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3062.2000.020104.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1034\/j.1399-3062.2000.020104.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3062.2000.020104.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"type":"print","value":"1398-2273"},{"type":"electronic","value":"1399-3062"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}